Alkame Expands Distribution Footprint to Encompass Nebraska

LAS VEGAS, NV--(Marketwired - May 18, 2015) - Alkame Holdings, Inc. (OTCQB: ALKM), a publicly traded health and wellness technology holding company with a focus on patentable, innovative, and eco-friendly products, is pleased to announce that Alkame Holdings, Inc. wholly owned subsidiary, Alkame Water, Inc.'s Ultimate Health and Wellness Water, which is a patented formula of premium oxygenated, alkaline and natural antioxidant bottled water products, has signed an exclusive Distribution Agreement with Omaha Nebraska-based Ideal Pure Water Inc. for the State of Nebraska.

According to Alkame Holdings, Inc. CEO, Robert Eakle, "We are excited and grateful for the opportunity to bring another proven distributor to our Alkame network. We are especially pleased to now work with Ideal Pure Water Inc., because they are based in Omaha, Nebraska, and can immediately bring our products to a significant customer base. We look forward to bringing our patented ultimate health and wellness water to consumers across the entire State of Nebraska and beyond."

About Alkame Holdings, Inc. (ALKM)
Alkame Holdings, Inc. is a publicly traded health and technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiary, Alkame Water, Inc., markets and distributes micro-clustered, alkaline, antioxidant and oxygenated bottled water utilizing an exclusive patented formula and technology. Alkame uses this patented technology to create water with several unique properties which allow the body to absorb and utilize it more efficiently and help to achieve an optimal pH balance. This patented technology also increases the available oxygen content and absorbability which equates to more fuel for improved metabolic efficiency, boosted immune system, and improved cardio respiratory function.

For more information visit: www.alkameholdingsinc.com

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.